Differentiation of Human Adipose-Derived Stem Cells into “Brite” (Brown-in-White) Adipocytes by Pisani, Didier F. et al.
ORIGINAL RESEARCH ARTICLE
published: 2 November 2011
doi: 10.3389/fendo.2011.00087
Differentiation of human adipose-derived stem cells into
“brite” (brown-in-white) adipocytes
Didier F. Pisani
1,2, Mansour Djedaini
1,2, Guillaume E. Beranger
1,2, Christian Elabd
1,2,3, Marcel Scheideler
4,
GérardAilhaud
1,2 and Ez-ZoubirAmri
1,2*
1 Institut de Biologie du Développement et Cancer, Université de Nice Sophia-Antipolis, Nice, France
2 CNRS UMR 6543, Institut de Biologie du Développement et Cancer, Nice, France
3 Department of Bioengineering, Institute for Quantitative Biosciences, University of California Berkeley, Berkeley, CA, USA
4 Institute for Genomics and Bioinformatics, Graz University ofTechnology, Graz, Austria
Edited by:
Patrick Seale, University of
Pennsylvania, USA
Reviewed by:
Miguel Lopez, University of Santiago
de Compostela, Spain
Darlene Evans Berryman, Ohio
University, USA
Anthony Scime,York University,
Canada
Rana Gupta, Dana-Farber Cancer
Institute, USA
*Correspondence:
Ez-Zoubir Amri, CNRS UMR 6543,
Institut de Biologie du
Développement et Cancer, Université
de Nice Sophia-Antipolis, 28 Avenue
de Valombrose 06107 , Nice Cedex 2,
France.
e-mail: amri@unice.fr
It is well established now that adult humans possess active brown adipose tissue (BAT)
which represents a potential pharmacological target to combat obesity and associated
diseases. Moreover thermogenic brown-like adipocytes (“brite adipocytes”) appear also
in mouse white adipose tissue (WAT) upon β3-adrenergic stimulation. We had previously
shown that human multipotent adipose-derived stem cells (hMADS) are able to differen-
tiate into cells which exhibit the key properties of human white adipocytes, and then to
convert into functional brown adipocytes upon PPARγ activation. In light of a wealth of data
indicating that thermogenic adipocytes from BAT and WAT have a distinct cellular origin,
we have characterized at the molecular level UCP1 positive hMADS adipocytes from both
sexes as brite adipocytes. Conversion of white to brown hMADS adipocytes is depen-
dent on PPARγ activation with rosiglitazone as the most potent agonist and is inhibited
b yaP P A R γ antagonist. In contrast to mouse cellular models, hMADS cells conversion
into brown adipocytes is weakly induced by BMP7 treatment and not modulated by acti-
vation of the Hedgehog pathway. So far no primary or clonal precursor cells of human
brown adipocytes have been obtained that can be used as a tool to develop therapeutic
drugs and to gain further insights into the molecular mechanisms of brown adipogenesis in
humans.Thus hMADS cells represent a suitable human cell model to delineate the forma-
tion and/or the uncoupling capacity of brown/brite adipocytes that could help to dissipate
caloric excess intake among individuals.
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INTRODUCTION
Obesity has reached epidemic proportions globally, with more
than one billion adults overweight and at least 300 million of
them clinically obese. In addition, at least 155 million children
worldwide are overweight or obese,according to the International
Obesity Task Force (Hossain et al., 2007). Obesity constitutes a
substantial risk factor for hypertension, type 2 diabetes, and car-
diovascular diseases implying tremendous burdens for the public
health care system. White adipose tissue (WAT) plays a central
role in the control of energy homeostasis (Ailhaud et al., 1992;
Rosen and Spiegelman,2006). In contrast to WAT,brown adipose
tissue (BAT) is specialized in adaptive thermogenesis in which
the uncoupling protein 1 (UCP1) plays a key role (Golozoubova
et al., 2006). The involvement of BAT in diet-induced thermo-
genesis has been recently shown in UCP1-ablated mice raised
at thermoneutrality (Feldmann et al., 2009). Of utmost interest,
recent data show that active BAT is indeed present as discrete and
small depots in healthy adult individuals (Nedergaard et al.,2007;
Cypessetal.,2009;Saitoetal.,2009;VanMarkenLichtenbeltetal.,
2009; Virtanen et al., 2009; Zingaretti et al., 2009) and represents
a new target to ﬁght obesity (Fruhbeck et al., 2009; Whittle et al.,
2011).
At the cellular level,a myogenic signature of brown adipocytes
andcellsortingofmuscleandWATderivedprogenitorsfavoradis-
tinct origin from that of white adipocytes (Timmons et al., 2007;
Crisan et al., 2008). In vivo lineage studies showed that brown
adipocytes from brown-fat depots share a common developmen-
tal origin with myoblasts (Seale et al., 2008). However, islands
of brown adipocytes are also detected in white fat depots of
rodents following chronic exposure to cold or pharmacological
stimulation of β3-adrenoreceptor (β3-AR). There is indeed evi-
dence that white adipocytes can be converted to brown-like fat
cells (Tiraby et al., 2003; Cinti, 2009a,b; Barbatelli et al., 2010).
Within traditional WAT depots, a particular type of adipocytes
occurs in rodents, corresponding to the“brite” (brown-in-white)
adipocytes. These cells express UCP1 and exhibit in vitro a ther-
mogenic response to β-AR agonists (Petrovic et al., 2010) that
could explain UCP1 expressing cells present as islets surrounded
by white adipocytes (Cousin et al., 1992; Xue et al., 2009). Most
importantly, in vivo, the capacity of obese mice to reduce their
fat mass in response to adrenergic stimulation by cold or β3-AR
agonist does not depend upon BAT whose amount is genetically
invariant among mouse strains but depends upon a genetic vari-
ability which affects the development of“brite”adipocytes within
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WAT depots (Guerra et al., 1998; Xue et al., 2007). Other external
cuesarefavoringthebrown-fatdifferentiation,e.g.,Hedgehogsig-
naling has been characterized as a determinant of brown-fat cell
fate (Pospisilik et al., 2010) whereas among bone morphogenetic
proteins(BMPs),BMP7speciﬁcallypromotesbrownadipogenesis
of murinemultipotentmesenchymalstemcells(Tsengetal.,2008;
Schulz et al.,2011).
We have reported the characterization of mesenchymal stem
cells from human adipose tissue of young male and female
donors [termed human multipotent adipose-derived stem cells
(hMADS)]whichexhibitataclonallevelanormalkaryotype,self-
renewal ability, the absence of tumorigenicity (Rodriguez et al.,
2004, 2005a; Zaragosi et al., 2006; Elabd et al., 2007; Fontaine
et al., 2008), and are able to convert into functional brown-like
adipocytes (Elabd et al., 2009). Owing to recent data show-
ing that thermogenic adipocytes from BAT and WAT originate
from distinct origin, the question raised whether UCP1-positive
hMADS adipocytes from both sexes are classical brown or“brite”
adipocytes.Hereinweprovideevidenceatthemolecularlevelthat
these cells share similarities with mouse brite adipocytes. How-
ever, in contrast to mouse cellular models, brown adipogenesis is
only slightly induced by BMP7 treatment and not modulated by
activation of the Hedgehog pathway. Thus hMADS cells represent
a suitable human cell model to gain insights in the formation of
brite adipocytes that could help to dissipate caloric excess intake.
MATERIALS AND METHODS
REAGENTS
Cell culture media, serum, buffers, and trypsin were purchased
from Lonza Verviers (Verviers, Belgium) and cell culture reagents
from Sigma-Aldrich Chimie (Saint-Quentin Fallavier, France).
Rosiglitazone was purchased from BertinPharma (Montigny le
bretonneux, France).
CELL CULTURE
The establishment and characterization of the multipotency
and self-renewal capacity of hMADS cells have been described
(Rodriguez et al., 2004, 2005b; Elabd et al., 2007, 2009). In the
experiments reported herein hMADS-1, 2, and 3 cells, estab-
lished respectively, from the umbilical fat pad of a 31-month-old
female donor, from the pubic region fat pad of a 5-year-old male
donor and the prepubic fat pad of a 4-month-old male,were used
between passages 16 and 35 corresponding from 35 to 100 popu-
lation doublings. Cells were seeded at a density of 4500cells/cm2
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented
with 10% FCS, 2.5ng/ml hFGF2, 60μg/ml penicillin, and
50μg/ml streptomycin. The medium was changed every other
day and hFGF2 was removed when cells reached conﬂuence and
were triggered for differentiation at day 2 post-conﬂuence (desig-
nated as day 0). Cells were then maintained in DMEM/Ham’s F12
media supplemented with 10μg/ml transferrin, 0.85μM insulin,
0.2nMtriiodothyronine,1μMdexamethasone,500μMisobutyl-
methylxanthine. Three days later, the medium was changed
(dexamethasone and isobutyl-methylxanthine were omitted) and
100nM rosiglitazone were added for the indicated periods.
Media were then changed every other day and cells used at
theindicateddays.Glycerol-3-phosphatedehydrogenase(GPDH)
activity measurements and Oil Red O staining were performed as
described previously (Negrel et al.,1978; Bezy et al.,2005).
ISOLATION AND ANALYSIS OF RNA
TotalRNAwasextractedusingTRI-Reagentkit(Euromedex,Souf-
felweyersheim, France) according to the manufacturer’s instruc-
tions. Quality control for purity and integrity of RNA were
testedbyOD(260/280nM)measurementsandethidiumbromide-
stained agarose analysis. Reverse transcription-polymerase chain
reaction (RT-PCR) analysis was conducted as described previ-
ously (Rodriguez et al., 2004; Bezy et al., 2005; Zaragosi et al.,
2006;Elabdetal.,2007).Primersequences,designedusingPrimer
Express software (Applied Biosystems, Courtaboeuf, France), are
listed in Table 1 and were tested for their speciﬁcity, efﬁciency,
reproducibility, and dynamic range. For quantitative PCR, ﬁnal
reaction volume was 20μl using SYBR green master mix (Euro-
gentec, Angers, France) and assays were run on an ABI Prism
7700 real-time PCR machine (PerkinElmer Life and Analytical
Sciences,Boston,MA,USA).Analiquotof PCRproductswasana-
lyzedon2%ethidiumbromide-stainedagarose.Theexpressionof
selectedgeneswasnormalizedtothatofTATA-boxbindingprotein
(TBP) gene and quantiﬁed using the comparative-ΔCt method.
TBP expression did not vary along the adipocyte differentiation
of hMADS cells; we used also 36B4 and POLR2A genes as house-
keeping genes which gave similar data. Human skeletal muscle
RNA extracts were obtained from a previous study (Pisani et al.,
2010).
MITOCHONDRIA ANALYSIS
Livingcellsweresubmittedto100nMMitoTrackerRedFM(Invit-
rogen) for 45min at 37˚C. Cells were ﬁnally washed with pre-
warmed culture medium and visualized with an Axiovert micro-
scope(CarlZeiss,LePecq,France)andpictureswerecapturedand
treated with AxioVision software (Carl Zeiss).
CYTOCHROME C OXIDASE ACTIVITY DETERMINATIONS
Cells were disrupted using a polytron in 10mM Tris pH 8, 1mM
EDTA, and 0.25M Sucrose containing protease inhibitors. Cell
lysate was centrifuged at 750g for 10min with a pellet corre-
spondingtoanuclear-enrichedfraction.Thesupernatantwasthen
centrifuged at 10 000g for 20min, the pellet corresponding to
a mitochondrial-enriched fraction. The mitochondrial-enriched
fraction was used to determine Cytochrome c Oxidase activity
according to manufacturer’s instructions (Cytochrome c Oxidase
Assay kit, Sigma).
STATISTICAL ANALYSIS
Data are expressed as mean values±SEM and are analyzed
using the 2-tailed Student’s t-test. Differences were considered
statistically signiﬁcant at P ≤0.05.
RESULTS
UCP1, 2, AND 3 EXPRESSION DURING HMADS CELL DIFFERENTIATION
We showed previously that hMADS cells were able to differen-
tiate into white and brown adipocytes depending on the length
of activation of PPARγ by rosiglitazone (Elabd et al., 2009). For
hMADS-1 cells, originally established from the umbilical fat pad
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Table 1 | Sequence of primers used for gene expression analysis.
Gene Complete name Forward primer Reverse primer Accession N˚
UCP1 Uncoupling protein 1 GTGTGCCCAACTGTGCAATG CCAGGATCCAAGTCGCAAGA NM021833
UCP2 Uncoupling protein 2 GGCCTCACCGTGAGACCTTAC TGGCCTTGAACCCAACCAT NM003355
UCP3 Uncoupling protein 3 TCAGCCCCCTCGACTGTATG ACTTTCATCAGGGCCCGTTT NM003356.3
PPARγ Peroxisome proliferator activated
receptor gamma
AGCCTCATGAAGAGCCTTCCA TCCGGAAGAAACCCTTGCA NM005037
PGC-1α PPARg coactivator 1 alpha CTGTGTCACCACCCAAATCCTTAT TGTGTCGAGAAAAGGACCTTGA NM013261
PGC-1β PPARg coactivator 1 beta GCGAGAAGTACGGCTTCATCAC CAGCGCCCTTTGTCAAAGAG NM13 3263
PRDM16 PR domain containing 16 GAAACTTTATTGCCAATAGTGAGATGA CCGTCCACGATCTGCATGT NM022114
CIDEA Cell death-inducing DFFA-like effector A GGCAGGTTCACGTGTGGATA GAAACACAGTGTTTGGCTCAAGA NM001279
CPT1B Carnitine palmitoyltransferase 1B AAACAGTGCCAGGCGGTC CGTCTGCCAACGCCTTG NM_152246
ELOVL3 Fatty acid elongase 3 TTGGACCTTGACTTCTGCAA GGGCTATGGGGAATGAGG NM152310.1
AGT Angiotensinogen ACCTACGTCCACTTCCAAGG GTTGTCCACCCAGAACTCCT NM_00 0029.3
MEOX2 Mesenchyme homeobox 2 AGAGGAAAAGCGACAGCTCA AAGTTCTCTGATTTGCTCTTTGGT NM005924.4
ZIC1 Zic family member 1 TGGCGCTCACATTCCTCTAT GCATCTCAGCCCCCTAAAA NM_00 3412.3
LHX8 LIM homeobox 8 GTCGGACGTCTGGGTTTG ACGGAAGAAATAGGGGAAGC NM001001933.1
CtBP1 C-terminal binding protein 1 GCCTCAACGAGCACAACCA ACCAGGAAGGCCCCTTGTC NM001012614.1
CtBP2 C-terminal binding protein 2 CTGGTGGACGAGAAAGCCTTA GGCTGCCCCTCGTATCCT NM022802.2
NRIP1 Nuclear receptor interacting protein 1 TTGGAGACAGACGAACACTGA TCTACGCAAGGAGGAGGAGA NM_00 3489.3
LXR Liver-X-receptor CAGGGCTCCAGAAAGAGATG ACAGCTCCACCGCAGAGT NM005693.2
GPBAR1 G protein-coupled bile acid receptor 1 CCCAGGCTATCTTCCCAGC AGCAGGAGCCCATAGACTTCG NM001077191.1
DiO2 Deiodinase type 2 GTCACTGGTCAGCGTGGTTTT TTCTTCACATCCCCCAATCCT NM 000793.5
COX1 Cyclooxygenase 1 AGCAGCTGAGTGGCTATTTCCT CCAGTTCCAATACCGCAACCG NM080591.1
COX2 Cyclooxygenase 2 GAATCATTCACCAGGCAAATTG TCTGTACTGCGGGTGGAACA NM_00 0963.2
PTGiS Prostaglandine I2 synthase GCCACATAGCTCATAAGCTGTAGAAC AGTTGCTCATCCAGCATTTGC NM000961.3
PTGiR Prostaglandine I2 receptor AGCCTGGGCAAGACTGGAG TAGGTGAGGTTCCTGCACGAA NM_00 0960.3
TPK1 Thiamin pyrophosphokinase 1 CAAGGTGTTCGTGGTTGGC TTGAGTGAGGGCCTCTGGAC NM_00 1042482.1
FABP4 Fatty acid binding protein 4 TGTGCAGAAATGGGATGGAAA CAACGTCCCTTGGCTTATGCT NM_00 1442.2
ADIPOQ Adiponectin GCAGTCTGTGGTTCTGATTCCATAC GCCCTTGAGTCGTGGTTTCC NM 00 479 7 .3
RARRES2 Chemerin GGAATATTTGTGAGGCTGGAA CAGGCATTTCCGTTTCCTC NM002889.3
PANK3 Pantothenate kinase 3 CATTGCAGACGGTGCTATGT GTTTGTGCAGGTGGAGGTTT NM024594.3
HOXC9 Homeobox C9 CAGCAAGCACAAAGAGGAGA CGACGGTCCCTGGTTAAATAC NM006897 .1
DPT Dermatopontin CGAGGAGCAACAACCACTTT CGGCACATTATGAACTTCCA NM001937 .4
LEP Leptin AGGGAGACCGAGCGCTTTC TGCATCTCCACACACCAAACC NM_00 0230.2
Gli1 Glioma-associated oncogene homolog 1 TGCAGTAAAGCCTTCAGCAATG TTTTCGCAGCGAGCTAGGAT NM001167609.1
Myf5 Myogenic factor 5 GATCACCTCCTCAGAGCAACCT GTGCTGGCAACTGGAGAGAGA NM005593.2
TBP TATA-box binding protein CACGAACCACGGCACTGATT TTTTCTTGCTGCCAGTCTGGAC NM003194
of a31-month-oldfemaledonor,a6-dayexposuretorosiglitazone
(betweendays3and9)provedtobeoptimalforthecellstobecome
white adipocytes. As shown in Figures 1A,B, further exposure of
thecellstorosiglitazonedidnotaltertheoveralladipogenesislevel
perse sincetreatmentbetweendays3and16broughtnochangein
triglycerideaccumulation(OilRedOstaining)andGPDHactivity.
Under this condition, as shown in Figure 1C, a dramatic increase
in the expression of UCP1 mRNA was observed. Interestingly,
when hMADS-1 cells were ﬁrst differentiated as above into white
adipocytes and rosiglitazone being removed for the next 5days,
a further 2-day rosiglitazone exposure (between days 14 and 16)
was sufﬁcient to stimulate the expression of UCP1 (Figure 1C).
In order to extend these observations, hMADS-2 and hMADS-3
cells,establishedrespectivelyfromthepubicfatpadofa5-year-old
male donor and the prepubic fat pad of a 4-month-old male,were
usedandgavesimilarresults(Figure1C).Undertheseconditions,
UCP1proteincouldbedetectedbyimmunoblottinganalysis(data
not shown).
We then measured for the expression of two other members
of the UCP family, UCP2 and UCP3. The expression of UCP2
mRNA was induced during adipogenesis of hMADS-1, 2, and 3
cells,anditsexpressionwaspartiallybutnotsigniﬁcantlyenhanced
by the duration of rosiglitazone treatment (Figure 1D). Inter-
estingly, UCP3 mRNA was barely detected (100–200 times lower
as compared to skeletal muscle cells), was not induced during
adipogenesis and remained insensitive to rosiglitazone treatment
(Figure 1E).
UCP1 INDUCTION IS DEPENDENT UPON PPARγ ACTIVATION
Among members of the thiazolidinedione family, rosiglitazone
is known as a high-afﬁnity ligand of PPARγ. We therefore car-
ried out a comparative study with other thiazolidinediones, i.e.,
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FIGURE 1 | Conversion of hMADS cells into brown- like adipocytes.
hMADS-1, 2, and 3 cells were induced to differentiate into adipocytes as
described under the Section “Materials and Methods.” Hundred nanometer
rosiglitazone was added during the indicated periods of treatment. At day
16, (A) cells were ﬁxed and stained by Oil Red O, (B) GPDH activity was
determined, and (C–E) UCP1, UCP2, and UCP3 mRNA levels, respectively,
were measured by quantitative RT-PCR. Results are mean±SEM of three
(B,C) or two (D,E) independent experiments. Results in (C) and (D) are
expressed by taking as 100% the value obtained for rosiglitazone treatment
between days 3 and 16. In (E), human skeletal muscle cells were used as
positive control for UCP3 expression. Results in (E) are expressed taking as
100% the value obtained for skeletal muscle cells. *p <0.05 vs. cells
treated between days 3 and 9.
troglitazone and ciglitazone, with respect to the induction of
UCP1 gene expression. For this purpose, hMADS-2 cells were
ﬁrst differentiated into white adipocytes as above, i.e., rosiglita-
zone treatment between days 3 and 9 followed by its removal
for the next 5days, were then exposed to increasing concentra-
tions of various thiazolidinediones between days 14 and 16. The
levels of UCP1 mRNA were analyzed by quantitative RT-PCR at
day 16. As shown in Figure 2A, troglitazone and ciglitazone were
able to induce UCP1 expression in a dose-dependent manner.
FIGURE 2 |Activation of PPARγ is involved in the conversion of white
to brown adipocytes. hMADS-2 cells were induced to differentiate into
white adipocytes in the presence of 100nM rosiglitazone between days 3
and 9, and then treated with various component as indicated between days
14 and 16. (A) Effect of various PPARγ agonists (Rosiglitazone,Troglitazone,
and Ciglitazone) analyzed by quantitative RT-PCR of UCP1 gene expression.
(B) Effect of the PPARγ antagonist GW9662 on UCP1 expression
stimulated by rosiglitazone. Results are the mean±SEM of two
independent experiments. Results are expressed by taking as 100% the
value obtained at 100nM rosiglitazone. *p<0.05 vs. cells exposed to
100nM rosiglitazone between days 3–9 and days 14–16.
Clearly, the potency of rosiglitazone was already maximal at a
dose where the effects of troglitazone and ciglitazone were weak.
Inordertogainfurtherinsightsintothecriticalroleof PPARγ,we
tested whether a speciﬁc PPARγ antagonist (GW9662) was able to
abolish the effect of rosiglitazone on UCP1 expression. As above,
hMADS-2 cells were ﬁrst differentiated into white adipocytes,
then treated or not with 100nM rosiglitazone in the presence
or absence of the PPARγ antagonist. As shown in Figure 2B the
rosiglitazone-induced UCP1 mRNA expression was abolished in
a dose-dependent manner by GW9662. Of note,GW9662 showed
no effect on untreated hMADS cells. Similar data were observed
using hMADS-3 cells (data not shown). Altogether, these obser-
vations demonstrated that induction of UCP1 was dependent on
PPARγ activation and that rosiglitazone was the most efﬁcient
agonist in this process.
CHARACTERIZATION OF MITOCHONDRIOGENESIS IN DIFFERENTIATED
hMADS ADIPOCYTES
As abundance of mitochondria is higher in brown as compared
to white fat cells, we tested whether mitochondriogenesis was
affected in the“browning”process of hMADS cells. Clearly, more
mitochondria were observed in brown-like adipocytes as com-
pared to white adipocytes (Figure 3A). This observation was
further supported by quantitative RT-PCR analysis of CPT1B,
a fatty acid transporter of the outer mitochondrial membrane
(Figure 3B). Under these conditions, CPT1B mRNA levels were
10-fold higher in brown-like adipocytes as compared to white
adipocytes. Furthermore, the increase of CPT1B mRNA levels
upon rosiglitazone treatment was similar to that observed for
UCP1 (Figure 1C).
Finally, we measured the Cytochrome c oxidase activity in this
fraction as an index of respiratory chain activity. As expected,
Cytochrome c oxidase activity was higher in UCP1-containing
fractions from hMADS cells chronically treated as compared to
cells treated between days 3 and 9 (Figure 3C). Thus, hMADS
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FIGURE 3 | Mitochondriogenesis of hMADS cells after conversion to
brown-like adipocytes. hMADS-2 cells were induced to differentiate into
adipocytes in the presence of 100nM rosiglitazone between days 3 and 9
or between days 3 and 16. Alternatively, after removal at day 9,
rosiglitazone was re-added or not at day 14 for 2days. (A) Mitochondria
visualized by epiﬂuorescence in living cells in the presence of the
mitotracker dye, (B) CPT1B mRNA levels determined at day 16 by
quantitative RT-PCR in hMADS-1, 2, and 3 cells and (C) Cytochrome c
oxidase activity determined at day 16. Results are mean±SEM (B,C) and
are representative experiments (A) of three independent experiments
performed on different series of cells. *p<0.05 vs. cells treated between
days 3 and 9.
adipocytes expressing UCP1 display a signiﬁcant increase in
mitochondriogenesis accompanied by an increase in their respi-
ratory activity; both indicating the acquisition of a brown-like
phenotype.As brown-like adipocytes arise from white adipocytes,
brown-like adipocytes can be deﬁned at ﬁrst sight under our
conditions as brite adipocytes.
ANALYSIS OF GENE EXPRESSION IN hMADS-DERIVED BRITE
ADIPOCYTES
Recently,studiesof mousemodelhavedescribedgeneswithdiffer-
ential expression in white vs. brown adipocytes (Vernochet et al.,
2009; Petrovic et al., 2010). Therefore we aimed at analyzing the
expression of a large set of these genes in white vs. brown-like
hMADS adipocytes.
First, we analyzed the expression of Myf5 known to be a mol-
ecular signature common to brown-fat and skeletal muscle cells
(Sealeetal.,2008).Myf5expressionwasnotdetectableinprolifer-
atingordifferentiatedhMADScellsoriginatingfromthreedonors
(data not shown).
Table 2 summarized the expression values (ΔCt referred to
TBP) of different genes in hMADS cells at day 9 of adipocyte
differentiation as well as day 16 of white and brite differentia-
tion of hMADS-2 and 3 cells. White and brite hMADS adipocytes
expressed classical adipogenic markers (FABP4, ADIPOQ, RAR-
RES2, PANK3, PPARγ, and low level of LXR) at similar levels.
In addition, hMADS brite adipocytes expressed UCP1, CPT1B,
CIDEA, and ELOVL3, four genes found to be highly expressed
in mouse brite adipocytes (Petrovic et al., 2010). Conversely,
these cells did not express ZIC1 and LHX8, two genuine brown
adipocyte speciﬁc genes (Vernochet et al., 2009). Interestingly,
hMADS cells expressed PRDM16, MEOX2, and AGT at the
same level in both white and brite adipocytes. With respect to
white adipocyte speciﬁc genes, it is noticeable that leptin (LEP)
and DPT but not HOXC9 levels decreased with brite adipocyte
formation.
Co-activators (PGC1α, PGC1β) and co-repressors (CtBP1,
CtBP2, NRIP1) of PPARγ were also expressed, demonstrating the
abilityofthesecellstomodulatePPARsignalingpathways.hMADS
cellsalsoexpressedotherclassicalcomponentsofbrownadipocyte
signalingsuchasDiO2(thyroidhormonepathway),COX1,COX2,
PGTiS, and PGTiR (arachidonic acid pathway) and interestingly,
an increase in the bile acid receptor, GPBAR1.
Altogether, these observations clearly conﬁrmed the “brite”
phenotype of hMADS adipocytes as they display both an origin
and a molecular signature distinct from those of genuine brown
adipocytes.
EFFECTS OF HEDGEHOG AND BMP SIGNALING EFFECTORS ON BRITE
hMADS CELL FORMATION
As conversion of hMADS cells into brite adipocytes is dependent
uponPPARγactivation,webecameinterestedindecipheringpath-
ways that are independent of rosiglitazone treatment. It has been
showninmousemodelsthatHedgehogandBMPpathwaysmodu-
latedtheformationofbrownadipocytes(Leeetal.,2008;Pospisilik
etal.,2010;Schulzetal.,2011).WeanalyzedUCP1expressionafter
activationoftheHedgehogpathway,usingtwoknownactivatorsof
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Table 2 |Analysis of white and brown speciﬁc markers.
hMADS-2 hMADS-3
Day 9 Day 16 Day 16 Day 9 Day 16 Day 16
“White
adipocyte”
“Brite
adipocyte”
Britevs.
white
“White
adipocyte”
“Brite
adipocyte”
Britevs.
white
Brown markers UCP1 0.376 5.231 138.1 26.393 0.060 2.400 45.50 18.958
CPT1B 0.322 0.147 1.757 11.949 0.020 0.110 1.340 12.182
CIDEA 0.019 0.041 0.076 1.857 0.020 0.010 0.028 2.800
ELOVL3 0.449 1.246 2.006 1.610 0.600 0.788 1.332 1.691
AGT 0.805 0.140 0.131 0.938 0.275 0.059 0.033 0.564
PRDM16 0.027 0.024 0.017 0.731 0.028 0.036 0.027 0.750
MEOX 2 0.016 0.019 0.020 1.035 0.030 0.013 0.009 0.705
ZIC1 nd nd nd nd 0.027 0.018 0.018 1.027
LHX8 nd nd nd nd nd nd nd nd
Brown/white markers FABP4 263.0 94.0 305.0 3.245 317 .0 206.0 390.0 1.893
ADIPOQ 105.0 31.0 138.0 4.452 69.00 27 .00 96.00 3.556
RARRES2 0.237 0.513 0.650 1.266 1.002 1.976 1.425 0.721
PANK 3 2.397 5.035 5.996 1.191 0.979 3.421 2.454 0.717
White markers HoxC9 0.679 0.514 0.710 1.381 0.591 0.648 0.550 0.849
DPT 3.264 1.964 1.096 0.558 18.306 7 .310 6.908 0.945
LEP 0.707 0.406 0.25 0.616 1.392 0.244 0.158 0.648
PPAR complex PGC1α 0.431 0.340 0.494 1.453 0.940 0.320 0.400 1.250
PGC1β 0.229 0.211 0.220 1.042 0.190 0.190 0.240 1.263
PPARγ 3.145 13.310 10.598 0.796 10.200 9.500 10.500 1.105
CtBP1 2.260 7 .300 6.200 0.849 1.820 6.100 6.400 1.049
CtBP2 1.110 1.910 18.200 9.529 2.280 2.540 11.700 4.606
NRIP1 1.442 1.066 1.597 1.499 1.140 0.630 0.750 1.190
LXR 0.110 8.000 12.600 1.575 0.150 8.500 20.300 2.388
Receptor/enzyme
involved in white and
brown activation
GPBAR1 0.309 0.120 0.209 1.743 0.118 0.056 0.084 1.489
DiO2 0.060 0.051 0.056 1.103 0.041 0.055 0.057 1.026
COX2 0.004 0.019 0.010 0.538 0.030 0.041 0.039 0.951
COX1 0.708 0.135 0.125 0.926 0.440 0.140 0.150 1.071
PTGiS 1.416 nd nd nd 0.390 0.910 0.440 0.484
PTGiR 0.008 0.123 0.145 1.178 0.040 0.080 0.118 1.475
TPK1 1.621 1.551 1.292 0.833 0.633 1.040 0.841 0.809
hMADS-2 and 3 cells were induced to differentiate into adipocytes in the presence of 100nM rosiglitazone between days 3 and 9 or between days 3 and 16. Expression
of various markers described previously was analyzed by quantitative RT-PCR.The expression values (ΔCt referred toTBP) mRNA in hMADS cells at the indicated.
Genes indicated in italics and bold are highly expressed in white adipocyte and in brown adipocyte conditions, respectively.
smoothen, i.e., purmorphamine and smoothened agonist (SAG).
hMADS cells that were differentiated in the presence of rosigli-
tazone either between day 3 and 9 or between day 3 and 16
were exposed to the two compounds and analyzed at day 16. As
expected, the expression of Gli1 mRNA (Figure 4A), a marker of
the activation of Hedgehog signaling (Hooper and Scott, 2005),
was observed. However, neither purmorphamine nor SAG were
able to substitute to rosiglitazone and to modulate the expression
of UCP1 or FABP4.
In a similar way we tested whether BMPs could induce the
“browning” of hMADS cells. hMADS cells, in the presence or
absence of rosiglitazone between days 3 and 9, were treated with
or without 10nM BMP2 or BMP7. As shown in Figure 4B,n e i -
ther BMP2 nor BMP7 affected adipogenesis of hMADS cells, as
illustrated by the expression of FABP4 and only induced weakly
the formation of brite adipocytes as illustrated by the expression
of UCP1 and CIDEA.
DISCUSSION
Recent advances in the developmental analysis of white and
brownprogenitorsdemonstratedadistinctorigin(Timmonsetal.,
2007; Crisan et al., 2008). Furthermore, brown-like adipocytes
are found in white fat depots upon physiological or pharmaco-
logical stimulation and there is evidence that white adipocytes
can be converted to brown-like fat cells (Tiraby et al., 2003;
Cinti,2009a,b).Arecentstudydescribedmouse“brite”adipocytes,
obtained upon chronic PPARγ activation of primary cultures of
white adipocyte precursors (Petrovic et al., 2010), which may
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FIGURE4|E f f e c to fHedgehog and BMP signaling in the conversion
of white to brown adipocytes. hMADS-2 cells were induced to
differentiate into adipocytes in presence of 100nM rosiglitazone at the
indicate times. (A), Purmorphamine (purmo) or smoothened agonist (SAG)
as effectors of the Hedgehog signaling pathway were added between
days 14 and 18.Their effects were analyzed by measuring UCP1, FABP4,
and Gli1 mRNA expression. (B) hMADS-2 cells were treated or not with
10nM BMP2 or BMP7 between days 0 and 16, and analyzed at day 16.
Results are the mean±SEM of three independent experiments and are
expressed by taking as 100% the value obtained for 100nM rosiglitazone
treatment between days 14 and 18. *p<0.05 vs. cells treated only by
rosiglitazone 100nM.
explain the UCP1 expression found in islets surrounded by white
adipocytes(Cousinetal.,1992;Xue et al.,2009). In adult humans,
the increase of white to“brite”adipocyte conversion and activity,
taking advantage of the important mass of WAT,could represent a
novel strategy to combat overweight/obesity as a result of energy
imbalance. Unfortunately, detailed investigations are hampered
ex vivo by the unavailability of human brite and genuine brown
adipocytes.
The observations reported herein emphasize that hMADS
cells can differentiate into brite adipocytes. Their differentia-
tion is associated with an increase of mitochondrial markers
(Figure3). During proliferation and differentiation,hMADS cells
do not express Myf5 indicating that a common signature with
myoblasts can be ruled out. Analyzing the expression pattern
of genes known to be associated with brown or brite murine
adipocytes, clearly demonstrate the brite signature of converted
hMADS cells. Indeed, these cells express brown adipocytes mark-
ers (PPARα, CPT1B, ELOVL3, CIDEA, PGC1a, and UCP1) and
do not (ZIC1, LHX8) or barely express other speciﬁc markers
(PRDM16, MEOX2) of genuine mouse brown adipocytes. More-
over, hMADS cells express well-known components of brown
adipocyte signaling, demonstrating that these cells are able to
respond to various signals such as α- and β-adrenergic agonists,
bile acids, fatty acids and prostaglandins, thyroid hormone, and
the natriuretic peptide (Table 2; Rodriguez et al., 2004; Elabd
et al., 2009). Therefore, hMADS cells can be used as a human cell
modeltoanalyzevariousbrownmodulatingsignalsthathavebeen
describedinrodents.OurresultsclearlyemphasizeHedgehogand
BMPs signaling as striking examples of the discrepancies exist-
ing between human and rodents (Fontaine et al., 2008; Svensson
et al., 2011). Actually, it has been previously shown that activa-
tion of Hedgehog signaling in vivo and in vitro impairs white
but not brown adipocyte differentiation (Pospisilik et al., 2010).
Herein we showed that treatment of hMADS cells with Hedge-
hog activators did not affect white or brite adipocyte formation
(Figure 4A). Furthermore, our data show that BMP7 induces
weakly brite adipocyte formation of hMADS cells, in contrast
to earlier observations in mouse cell models (Tseng et al., 2008;
Schulz et al., 2011) despite the fact that hMADS cells do express
functional BMP receptors (Zaragosi et al., 2010; and data not
shown).
Taken together, our data demonstrated that differentiated
brown-like hMADS adipocytes are representative of the so-called
brite adipocytes recently described in mice (Petrovic et al., 2010)
though signiﬁcant differences are observed with regard to signal-
ing cues favoring brown adipogenesis. In conclusion, our human
cellmodelcouldcontributetoshedsomelightonthemechanisms
involved in the browning process of white adipocytes and could
help in identifying drugs involved in this phenomenon.
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